{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"8.8","value":"1.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"}],"units":"Participants"}],"description":"Time from first bb2121 infusion to first documentation of response of PR or better.","dispersionType":"Full Range","groups":[{"description":"BB2121","id":"OG000","title":"BB2121"}],"paramType":"MEDIAN","populationDescription":"All Treated Participants with a CR or PR as per IRC","reportingStatus":"POSTED","timeFrame":"From first dose to initial response (approximately on average 1.2 months, max of 8.8 months)","title":"Time to Response","type":"SECONDARY","unitOfMeasure":"Months"}